Nektar Therapeutics | NKTR - Себестоимость





Себестоимость Изменить Дата
Agios Pharmaceuticals USD 1.32M 560K 2026-03
ALKERMES USD 46.21M 5.38M 2025-12
Amgen USD 1.6B 187M 2026-03
Baxter International USD 1.81B 587M 2026-03
BioCryst Pharmaceuticals USD 9.52M 7.34M 2025-12
Biogen USD 797.5M 302M 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Cara Therapeutics USD 0 0 2025-03
Cipla INR 29.1B 1.16B 2025-12
Dr.Reddys Laboratories INR 36.16B 3.75B 2025-12
Eisai JPY 51.08B 5.56B 2025-12
Eli Lilly USD 3.58B 205M 2026-03
Esperion Therapeutics USD 27.85M 13.43M 2025-12
Exelixis USD 26.48M 7.91M 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
GlaxoSmithKline GBP 1.88B 736M 2026-03
Grifols EUR 1.51B 184.45M 2025-12
Halozyme Therapeutics USD 102.15M 29.14M 2025-12
Incyte USD 104.5M 16.68M 2026-03
Ionis Pharmaceuticals USD 3M 5M 2026-03
Ironwood Pharmaceuticals USD 29.83M 560K 2024-09
Karyopharm Therapeutics USD 1.48M 35.95M 2025-12
MacroGenics USD 10.12M 34.18M 2025-12
Merck USD 2.94B 380M 2026-03
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Novartis USD 3.46B 83M 2026-03
Pfizer USD 6.29B 2.12B 2025-12
Roche Holding CHF 8.48B 4.61B 2025-12
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
Takeda JPY 401.15B 184.07B 2025-12
Teva Pharmaceutical Industries USD 2.01B 46M 2026-03
Xencor USD 61.66M 50.95M 2025-06